Latest News and Press Releases

Oslo, Norway, 23 August 2021 - PCI Biotech’s (OSE: PCIB) first half-year 2021 interim report will be released on 31 August 2021 at 07.00 CEST. The interim report and presentation will be made...

Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new...

Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...

Oslo, 28 May 2021. The Annual General Meeting in PCI Biotech Holding ASA took place today, 28 May 2021. All proposals were resolved by the Annual General Meeting as presented in the notice convening...

Oslo, 27 May 2021. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo, Norway 7 May 2021 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 28 May 2021 at 10:00am (CEST). Due to...

Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...

Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused...

Oslo (Norway), 30 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...

Oslo, Norway, 30 April 2021 - PCI Biotech’s (OSE: PCIB) first quarter 2021 interim report will be released on 7 May 2021 at 07.00 CEST. The interim report and presentation will be made available on...